A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.

Sarit AssoulineLaura C MichaelisMegan OthusAnnette E HayRoland B WalterMeagan A JacobyMark A SchroederGeoffrey L UyLisa Y LawFaisal CheemaKendra L SweetAdam S AschJijun Jane LiuAnna B MoseleyTracy MaherLaura L KingsburyMin FangJerald RadichRichard F LittleHarry P Erba

Published in: Leukemia & lymphoma (2022)

Keyphrases

acute myeloid leukemia
phase ii
newly diagnosed
allogeneic hematopoietic stem cell transplantation
clinical trial
open label
small molecule
physical activity
phase iii
randomized controlled trial
acute lymphoblastic leukemia
placebo controlled
bone marrow